about
Predictive value of urinary retinol binding protein for graft dysfunction after kidney transplantationMorbimortality of pandemic influenza A H1N1 infection in kidney transplant recipients requiring hospitalization: a comparative analysis with nonimmunocompromised patients.Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection.Randomized Trial of Machine Perfusion Versus Cold Storage in Recipients of Deceased Donor Kidney Transplants With High Incidence of Delayed Graft FunctionBlockade of Notch ligand δ1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generationProlonged Delayed Graft Function Is Associated with Inferior Patient and Kidney Allograft Survivals.Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant.Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.What is the impact of surgical site infection on graft function in kidney transplant recipients?Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome.Limitations of the interpretation and extrapolation of clinical trial data in kidney transplant recipients.Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.Liver transplantation in Latin America: the state-of-the-art and future trends.Predicting delayed kidney graft function with gene expression in preimplantation biopsies and first-day posttransplant blood.Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study.Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center.Melanized fungal infections in kidney transplant recipients: contributions to optimize clinical management.Pregnancy after kidney transplantation: high rates of maternal complications.Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation.Renal transplantation in human immunodeficiency virus-infected recipients: a case-control study from the Brazilian experience.Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.IgA NEPHROPATHY IN PATIENTS RECEIVING A RENAL TRANSPLANT.Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.Outcomes in obese kidney transplant recipients.Past and current hepatitis E virus infection in renal transplant patients.Long-term exposure to belatacept in recipients of extended criteria donor kidneys.First report and molecular characterization of hepatitis E virus infection in renal transplant recipients in Brazil.The evolution of diabetic chronic complications after pancreas transplantationComparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.Transcription-mediated amplification (TMA) for the assessment of viremia in hemodialysis patients with hepatitis C.Lack of impact of hepatitis C virus coinfection in end-stage renal disease patients with hepatitis B virus infection.Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients.Risk factors associated with graft loss and patient survival after kidney transplantation.Adverse effects of pregnancy on renal allograft function.Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease?CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection.Hepatitis C virus infection in renal transplant patients: a comparative study with immunocompetent patients.
P50
Q28182098-73D6FC73-45EF-432D-B802-2D8DF80F1082Q30411112-03B69194-025F-40FD-8119-9FA0748158BBQ33379616-1BA412E0-F189-41CC-8210-237FADD759E3Q33719822-F38D7A0C-049B-47CC-B31A-7C2A7A8EA1F1Q35401923-9A299756-1297-431D-9416-AE1AE4635A37Q35872277-176561FF-5BB9-45FF-95AE-50843A9ABD1BQ37548133-B5A3BBDC-DF8E-4D04-81AC-41FBF77BA242Q37745691-241D4F3A-32E5-454D-9B8E-837F80184AD5Q37766292-C61B010E-6151-4C6F-B69D-0035B9FB1E32Q37768326-29E785E7-EF7B-4B80-B5D1-D99A47546A23Q38700286-171D8B20-729C-47A9-8D8F-65B75EBEFB1CQ38896041-20EEC51D-BA60-4B54-8CB5-208060287860Q39148586-99CB6CB2-D09F-4767-807A-2730C1C0512BQ40018463-82ED51F8-146C-4175-BB13-CB117FA8CC02Q40199898-6CC55627-DF31-4EE9-8DE5-F7E602E13924Q40328463-8996F857-4366-4FC4-B1BC-6713CA8903D4Q40381930-1A8F76D0-873B-4F03-9244-29218E575F21Q40400737-09112F16-C16E-4A16-9FDF-DAE32DBCB10EQ40535469-C8A7973C-D1AF-49FF-897D-0A478BC856D9Q40583539-C1639FBD-136C-483D-9906-DAD02A606148Q40786129-C9608284-C209-4F5F-A746-BD189B62D920Q41145470-C66CA2BC-7AE4-4EDB-9DBC-B556B0A9A394Q41218897-750C43D0-1D7C-4ED8-8A0B-D45C1AF4898AQ41604375-762319B3-853F-4522-AA96-BD90BDD4C865Q42232143-54D3ECD5-1844-4D9B-AA92-9EEDF7188CE1Q42264108-E3840B92-1359-4D9E-847F-F1144AF57B4FQ42276350-F7FF8F91-EE8D-4B4F-A28B-FE8E6BE34D05Q42584341-B374C96B-2DA8-4708-A4F9-5AF45CC5B09EQ42974160-277A02FE-22D8-4F02-9C35-AFB92762F6B2Q42977752-3FF61878-DDC2-4A8B-AC7B-DC0912AC63CCQ42993304-87F677F8-1FD5-4CD7-9BBF-A0AF0E4F08FEQ42994992-3B70AADC-BCCA-4B0F-B5B3-1A1041306D2CQ43035620-52B7ADFD-D50F-40F5-99C7-6538650BFAF5Q43049555-7909EF3E-6378-492C-92CB-80B640CA92DBQ43241192-E8279636-80A2-406E-923D-AEC9B253CEDBQ43992354-0A588E45-FB70-491B-949D-FA39AB92994BQ44490720-A035B579-4DE7-46A3-86DF-83CCF36EFB6CQ44819549-1518C203-AD49-4493-B15C-6F33E4371BD0Q45402032-DE26A33A-748C-431E-83E2-37716962730EQ45422137-D7381F2C-2B00-4C73-BB0C-72AB59EB0F72
P50
description
researcher
@en
wetenschapper
@nl
name
José O Medina Pestana
@en
José O Medina Pestana
@nl
type
label
José O Medina Pestana
@en
José O Medina Pestana
@nl
prefLabel
José O Medina Pestana
@en
José O Medina Pestana
@nl
P106
P31
P496
0000-0003-3912-2980